Cargando…
The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation
PURPOSE: This study aimed to investigate the clinical impacts of the pretreatment peripheral blood ratios of lymphocytes, monocytes and neutrophils among patients with hypopharyngeal cancer/laryngeal cancer. PATIENTS AND METHODS: A total of 141 people with cases of hypopharyngeal cancer/laryngeal ca...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524172/ https://www.ncbi.nlm.nih.gov/pubmed/33061596 http://dx.doi.org/10.2147/CMAR.S275635 |
_version_ | 1783588504006033408 |
---|---|
author | Chuang, Hui-Ching Tsai, Ming-Hsien Lin, Yu-Tsai Chou, Ming-Huei Huang, Tai-Lin Chiu, Tai-Jan Lu, Hui Fang, Fu-Min Chien, Chih-Yen |
author_facet | Chuang, Hui-Ching Tsai, Ming-Hsien Lin, Yu-Tsai Chou, Ming-Huei Huang, Tai-Lin Chiu, Tai-Jan Lu, Hui Fang, Fu-Min Chien, Chih-Yen |
author_sort | Chuang, Hui-Ching |
collection | PubMed |
description | PURPOSE: This study aimed to investigate the clinical impacts of the pretreatment peripheral blood ratios of lymphocytes, monocytes and neutrophils among patients with hypopharyngeal cancer/laryngeal cancer. PATIENTS AND METHODS: A total of 141 people with cases of hypopharyngeal cancer/laryngeal cancer were enrolled to evaluate the clinical impacts of the systemic inflammation response index (SIRI), neutrophil–lymphocyte ratio (NLR) and lymphocyte–monocyte ratio (LMR) in pretreatment blood among patients with laryngeal/hypopharyngeal cancer between January 2012 and December 2014. RESULTS: Those patients with higher pretreatment LMR (>2.99) showed a significantly higher 5-year complete response rate (CR) (69% vs 31%) than those with lower LMR (≤2.99, p = 0.006). Additionally, those patients with lower pretreatment SIRI (<3.26) showed a significantly higher 5-year CR (90% vs 10%) than those with higher SIRI (≥3.26, p < 0.001). Patients with higher LMR had better 5-year overall survival (OS) (p = 0.01) and 5-year progression-free (PFS) (p = 0.005) rates than those with lower LMR in univariate analysis. Patients with lower SIRI had better 5-year OS (p < 0.001) and 5-year PFS (p < 0.001) than those with higher SIRI in univariate analysis. In the Cox regression analysis, SIRI (HR = 1.941, [95% CI: 1.223–3.081], p = 0.005) and N classification (HR = 2.203, [95% CI: 1.327–3.657], p = 0.002) were independent variables of 5-year OS. In addition, SIRI (HR= 2.127, [95% CI: 1.214–3.725], p = 0.008), T classification (HR = 2.18, [95% CI: 1.072–4.433], p = 0.031), and N classification (HR = 2.329, [95% CI: 1.395–3.889], p = 0.001) were independent variables of 5-year PFS. CONCLUSION: Pretreatment SIRI is superior to LMR in predicting treatment response and clinical outcomes among patients with laryngeal/hypopharyngeal cancer treated by CRT/RTO. SIRI may be adopted in the treatment of laryngeal/hypopharyngeal cancer by CRT/RTO. |
format | Online Article Text |
id | pubmed-7524172 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75241722020-10-14 The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation Chuang, Hui-Ching Tsai, Ming-Hsien Lin, Yu-Tsai Chou, Ming-Huei Huang, Tai-Lin Chiu, Tai-Jan Lu, Hui Fang, Fu-Min Chien, Chih-Yen Cancer Manag Res Original Research PURPOSE: This study aimed to investigate the clinical impacts of the pretreatment peripheral blood ratios of lymphocytes, monocytes and neutrophils among patients with hypopharyngeal cancer/laryngeal cancer. PATIENTS AND METHODS: A total of 141 people with cases of hypopharyngeal cancer/laryngeal cancer were enrolled to evaluate the clinical impacts of the systemic inflammation response index (SIRI), neutrophil–lymphocyte ratio (NLR) and lymphocyte–monocyte ratio (LMR) in pretreatment blood among patients with laryngeal/hypopharyngeal cancer between January 2012 and December 2014. RESULTS: Those patients with higher pretreatment LMR (>2.99) showed a significantly higher 5-year complete response rate (CR) (69% vs 31%) than those with lower LMR (≤2.99, p = 0.006). Additionally, those patients with lower pretreatment SIRI (<3.26) showed a significantly higher 5-year CR (90% vs 10%) than those with higher SIRI (≥3.26, p < 0.001). Patients with higher LMR had better 5-year overall survival (OS) (p = 0.01) and 5-year progression-free (PFS) (p = 0.005) rates than those with lower LMR in univariate analysis. Patients with lower SIRI had better 5-year OS (p < 0.001) and 5-year PFS (p < 0.001) than those with higher SIRI in univariate analysis. In the Cox regression analysis, SIRI (HR = 1.941, [95% CI: 1.223–3.081], p = 0.005) and N classification (HR = 2.203, [95% CI: 1.327–3.657], p = 0.002) were independent variables of 5-year OS. In addition, SIRI (HR= 2.127, [95% CI: 1.214–3.725], p = 0.008), T classification (HR = 2.18, [95% CI: 1.072–4.433], p = 0.031), and N classification (HR = 2.329, [95% CI: 1.395–3.889], p = 0.001) were independent variables of 5-year PFS. CONCLUSION: Pretreatment SIRI is superior to LMR in predicting treatment response and clinical outcomes among patients with laryngeal/hypopharyngeal cancer treated by CRT/RTO. SIRI may be adopted in the treatment of laryngeal/hypopharyngeal cancer by CRT/RTO. Dove 2020-09-25 /pmc/articles/PMC7524172/ /pubmed/33061596 http://dx.doi.org/10.2147/CMAR.S275635 Text en © 2020 Chuang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Chuang, Hui-Ching Tsai, Ming-Hsien Lin, Yu-Tsai Chou, Ming-Huei Huang, Tai-Lin Chiu, Tai-Jan Lu, Hui Fang, Fu-Min Chien, Chih-Yen The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation |
title | The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation |
title_full | The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation |
title_fullStr | The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation |
title_full_unstemmed | The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation |
title_short | The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation |
title_sort | clinical impacts of pretreatment peripheral blood ratio on lymphocytes, monocytes, and neutrophils among patients with laryngeal/hypopharyngeal cancer treated by chemoradiation/radiation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524172/ https://www.ncbi.nlm.nih.gov/pubmed/33061596 http://dx.doi.org/10.2147/CMAR.S275635 |
work_keys_str_mv | AT chuanghuiching theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT tsaiminghsien theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT linyutsai theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT chouminghuei theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT huangtailin theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT chiutaijan theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT luhui theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT fangfumin theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT chienchihyen theclinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT chuanghuiching clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT tsaiminghsien clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT linyutsai clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT chouminghuei clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT huangtailin clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT chiutaijan clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT luhui clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT fangfumin clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation AT chienchihyen clinicalimpactsofpretreatmentperipheralbloodratioonlymphocytesmonocytesandneutrophilsamongpatientswithlaryngealhypopharyngealcancertreatedbychemoradiationradiation |